Clinical Trials in Boulogne, France
5 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 2Phase 3
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Advanced Melanoma
Eikon Therapeutics740 enrolled107 locationsNCT06697301
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Non-small Cell Lung Cancer (NSCLC)KRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc.616 enrolled89 locationsNCT06162221
Recruiting
Phase 3
Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique129 enrolled40 locationsNCT06937905
Recruiting
Phase 2
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
Stage III NSCLC
Intergroupe Francophone de Cancerologie Thoracique152 enrolled25 locationsNCT06656598
Recruiting
Phase 4
3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children
Pyelonephritis Acute
Assistance Publique - Hôpitaux de Paris480 enrolled15 locationsNCT05544565
Recruiting
Not Applicable
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
Aortic Aneurysm, Abdominal
FCRE (Foundation for Cardiovascular Research and Education)204 enrolled32 locationsNCT04503395
Recruiting
Not Applicable
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
Non-small Cell Lung CancerEGFR Activating MutationEGFR DEL19+1 more
Intergroupe Francophone de Cancerologie Thoracique300 enrolled36 locationsNCT06053099